Research programme: macrolide antibacterials - GlaxoSmithKline

Drug Profile

Research programme: macrolide antibacterials - GlaxoSmithKline

Alternative Names: 4"-O-Arylalkenyl-8a-aza-8a-homoerythromycins azalides; Anti-inflammatory macrolides - GlaxoSmithKline; Macrolide antibacterials research programme: GlaxoSmithKline; PLD-146; PLR 1; PLR-18

Latest Information Update: 19 May 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline; PLIVA d.d.
  • Developer GlaxoSmithKline
  • Class Macrolides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Bacterial infections

Most Recent Events

  • 19 May 2008 Discontinued - Preclinical for Bacterial infections in European Union (unspecified route)
  • 05 May 2006 GlaxoSmithKline acquires the research arm of PLIVA
  • 20 Jul 2005 This programme is still in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top